Adjunctive traditional Chinese medicine therapy improves survival of liver cancer patients
Authors:
- 29 April 2015
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 35 (12) , 2595-2602
Abstract
Background: Traditional Chinese medicine (TCM) is an alternative treatment for cancer with its effect by stimulating host immune response for cytotoxic activity against liver cancer. No studies evaluated TCM treatment on survival of liver cancer patients.Patients and methods: This study determined whether the combination of TCM and conventional cancer treatment affects the survival of liver cancer patients. A retrospective cohort study was conducted in 127 237 newly diagnosed liver cancer patients from 2000 to 2009 in the National Health Insurance Program database.Results: Among these patients, 30 992 (24.36%) used TCM for liver cancer care. All patients were followed up until 2011. The mean follow‐up was 5.67 years (SD 1.47) for TCM users and 5.49 years (SD 3.64) for non‐TCM users. Compared with patients without TCM use, patients with TCM use were significantly associated with a decreased risk of death [hazard ratio (HR) = 0.65, 95% confidence interval (CI) = 0.64–0.66] with multivariate adjustment. A similar significant protective effect of TCM use across various subgroups of chronic liver diseases was also observed. Jia Wei Xiao Yao San (HR = 0.89, 95% CI = 0.81–0.96) and Chai Hu Shu Gan Tang (HR = 0.86, 95% CI = 0.78–0.95) were the most effective TCM agents that improved survival.Conclusions: This cohort study provided information that adjunctive therapy with TCM may improve the survival in liver cancer patients. Further studies are needed to confirm the potential role of TCM in HCC.Keywords
Funding Information
- China Medical University (A‐6‐1)
This publication has 17 references indexed in Scilit:
- Three advantages of using traditional Chinese medicine to prevent and treat tumorJournal of Integrative Medicine, 2014
- The roles of traditional Chinese medicine in gene therapyJournal of Integrative Medicine, 2014
- Mir-184 Post-Transcriptionally Regulates SOX7 Expression and Promotes Cell Proliferation in Human Hepatocellular CarcinomaPLOS ONE, 2014
- Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trialJournal of Integrative Medicine, 2013
- Utilization pattern of traditional Chinese medicine for liver cancer patients in TaiwanBMC Complementary and Alternative Medicine, 2012
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Liver cancer: Targeted future optionsWorld Journal of Hepatology, 2011
- Design and Endpoints of Clinical Trials in Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2008
- Frequency and pattern of Chinese herbal medicine prescriptions for chronic hepatitis in TaiwanJournal of Ethnopharmacology, 2008
- Evidence-based Chinese medicine for cancer therapyJournal of Ethnopharmacology, 2008